---
title: "Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: References"
description: "Reference list for the formulary evidence report on Lorundrostat (MLS-101, MT-4129) in Hypertension, in combination with other antihypertensive drugs. 198 cited documents."
canonical: "https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references"
published: "2026-11-18T10:43:00-05:00"
modified: "2026-11-18T10:43:00-05:00"
---

# Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: References

<a id="references"></a>

## 5 References

1. [Adler et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40658480/)
2. [Agarwal et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9119310/)
3. [Alnylam press release, ZENITH first patient dosed (2025)](https://www.businesswire.com/news/home/20251001569564/en)
4. [AstraZeneca BAXFENDY prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219878Orig1s000lbl.pdf)
5. [AstraZeneca press release, baxdrostat NDA acceptance (2025)](https://www.astrazeneca.com/media-centre/press-releases/2025/baxdrostat-new-drug-application-accepted-under-fda-priority-review-in-the-us-for-patients-with-hard-to-control-hypertension.html)
6. [AstraZeneca press release, Baxfendy EU CHMP opinion (2026)](https://www.astrazeneca.com/media-centre/press-releases/2026/baxfendy-recommended-for-approval-in-the-eu.html)
7. [AstraZeneca press release, BAXFENDY US approval (2026)](https://www.businesswire.com/news/home/20260518258445/en/)
8. [Azizi et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34010611/)
9. [Azizi et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9975904/)
10. [Azizi et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41794437/)
11. [Baker (2026)](https://pubmed.ncbi.nlm.nih.gov/42847224/)
12. [Bakris et al. (2024a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11094384/)
13. [Bakris et al. (2024b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10873804/)
14. [Beaney (2025)](https://www.clinicaltrialsarena.com/news/mineralys-therapeutics-stock-jumps-hypertension-trial-data/)
15. [Beyhaghi and Viera (2019)](https://pubmed.ncbi.nlm.nih.gov/30571548/)
16. [Blood Pressure Lowering Treatment Trialists' Collaboration (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8102467/)
17. [Blumenthal et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8511053/)
18. [Boehringer Ingelheim press release, EASi-KIDNEY update (2026)](https://www.boehringer-ingelheim.com/human-health/boehringer-provides-update-easi-kidney-trial)
19. [Brown et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7459427/)
20. [Bryant et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10987007/)
21. [Burgos et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40802954/)
22. [Calhoun et al. (2002)](https://pubmed.ncbi.nlm.nih.gov/12468575/)
23. [Carey et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6530990/)
24. [Carey et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6693520/)
25. [Carris and Smith (2015)](https://pubmed.ncbi.nlm.nih.gov/26115629/)
26. [Carris et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26084656/)
27. [CDC About High Blood Pressure (2026)](https://www.cdc.gov/high-blood-pressure/about/index.html)
28. [CDC High Blood Pressure Facts (2026)](https://www.cdc.gov/high-blood-pressure/data-research/facts-stats/index.html)
29. [Chang et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31679429/)
30. [ClinicalTrials.gov NCT02953132](https://clinicaltrials.gov/study/NCT02953132)
31. [ClinicalTrials.gov NCT05001945](https://clinicaltrials.gov/study/NCT05001945)
32. [ClinicalTrials.gov NCT05001945 results](https://clinicaltrials.gov/study/NCT05001945?tab=results)
33. [ClinicalTrials.gov NCT05769608](https://clinicaltrials.gov/study/NCT05769608)
34. [ClinicalTrials.gov NCT05968430](https://clinicaltrials.gov/study/NCT05968430)
35. [ClinicalTrials.gov NCT06150924](https://clinicaltrials.gov/study/NCT06150924)
36. [ClinicalTrials.gov NCT06150924 results](https://clinicaltrials.gov/study/NCT06150924?tab=results)
37. [ClinicalTrials.gov NCT06153693](https://clinicaltrials.gov/study/NCT06153693)
38. [ClinicalTrials.gov NCT06785454](https://clinicaltrials.gov/study/NCT06785454)
39. [CMS 2027 Part C and D Star Ratings Technical Notes (2026)](https://www.cms.gov/files/document/2027-tech-notes-2026-09-30.pdf)
40. [CMS 2027 Star Ratings Measures and Weights (2026)](https://www.cms.gov/files/document/2027-star-ratings-measures.pdf)
41. [CMS decision memo, renal denervation for uncontrolled hypertension (2025)](https://www.cms.gov/medicare-coverage-database/view/ncacal-decision-memo.aspx?proposed=N&NCAId=318)
42. [CMS NADAC, amiloride 5 mg (2026)](https://data.medicaid.gov/api/1/datastore/query/fbb83258-11c7-47f5-8b18-5f8e79f7e704/0?conditions[0][property]=ndc&conditions[0][value]=42794000502&conditions[0][operator]==&conditions[1][property]=effective_date&conditions[1][value]=2026-11-18&conditions[1][operator]==&limit=1)
43. [CMS NADAC, BAXFENDY 2 mg (2026)](https://data.medicaid.gov/api/1/datastore/query/fbb83258-11c7-47f5-8b18-5f8e79f7e704/0?conditions[0][property]=ndc&conditions[0][value]=00310600230&conditions[0][operator]==&conditions[1][property]=effective_date&conditions[1][value]=2026-11-18&conditions[1][operator]==&limit=1)
44. [CMS NADAC, eplerenone 50 mg (2026)](https://data.medicaid.gov/api/1/datastore/query/fbb83258-11c7-47f5-8b18-5f8e79f7e704/0?conditions[0][property]=ndc&conditions[0][value]=31722005030&conditions[0][operator]==&conditions[1][property]=effective_date&conditions[1][value]=2026-11-18&conditions[1][operator]==&limit=1)
45. [CMS NADAC, spironolactone 25 mg (2026)](https://data.medicaid.gov/api/1/datastore/query/fbb83258-11c7-47f5-8b18-5f8e79f7e704/0?conditions[0][property]=ndc&conditions[0][value]=53489014310&conditions[0][operator]==&conditions[1][property]=effective_date&conditions[1][value]=2026-11-18&conditions[1][operator]==&limit=1)
46. [CMS National Coverage Determination 20.19, ambulatory blood pressure monitoring (2019)](https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?ncdid=254)
47. [Cohen et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7965294/)
48. [Daugherty et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3343635/)
49. [de la Sierra et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21444835/)
50. [de la Sierra et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39247961/)
51. [Deragon et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12826897/)
52. [Desai et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35880517/)
53. [Desai et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12120674/)
54. [Dieleman et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11829247/)
55. [Dixon et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10625044/)
56. [Douma et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/18539224/)
57. [Durand et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28777133/)
58. [Dwyer et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12889919/)
59. [Earle et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13488949/)
60. [Elbahloul et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41645642/)
61. [Electronic Code of Federal Regulations, 21 CFR 312.21 (2026)](https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-312/subpart-B/section-312.21)
62. [Eli Lilly ZEPBOUND prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217806s013lbl.pdf)
63. [Ettehad et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26724178/)
64. [EU Clinical Trials Information System 2023-506425-12-00](https://euclinicaltrials.eu/ctis-public/view/2023-506425-12-00)
65. [Fang et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32369108/)
66. [FDA draft guidance, studies on a background of multiple antihypertensive drugs (2018)](https://www.fda.gov/media/114731/download)
67. [FDA guidance, hypertension labeling for cardiovascular outcome claims (2011)](https://www.fda.gov/media/134777/download)
68. [FDA guidance, ICH E1A extent of population exposure (1995)](https://www.fda.gov/media/71180/download)
69. [FDA NDA 217686 supplement approval letter (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/217686Orig1s004ltr.pdf)
70. [FDA NDA 219878 approval letter (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/219878Orig1s000ltr.pdf)
71. [FDA PMA database, Paradise Ultrasound Renal Denervation System (2023)](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P220023)
72. [FDA PMA database, Symplicity Spyral Renal Denervation System (2023)](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P220026)
73. [FDA Table of Surrogate Endpoints (2026)](https://www.fda.gov/drugs/development-resources/table-surrogate-endpoints-were-basis-drug-approval-or-licensure)
74. [Fioretti et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40738563/)
75. [Flack et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11533979/)
76. [Flack et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7618089/)
77. [Franklin et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13375916/)
78. [Fryar et al. (2024)](https://www.cdc.gov/nchs/products/databriefs/db511.htm)
79. [Gaddam et al. (2008)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2748247/)
80. [Geisler et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22981547/)
81. [Gupta et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28461599/)
82. [Henry et al. (2026)](https://mineralystx.com/wp-content/uploads/2026/11/ISPOREurope26_Henry_EPH1_POSTER.pdf)
83. [ICER evidence report (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_EvidenceReport_For-Publication_100126.pdf)
84. [ICER hypertension assessment page (2026)](https://icer.org/assessment/hypertension-2026/)
85. [ICER public comment folio (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_Public-Comment-Folio_100126.pdf)
86. [ICER public meeting slides (2026)](https://icer.org/wp-content/uploads/2026/03/ICER_Hypertension_Public-Meeting-Slides_102926_For_Publication.pdf)
87. [ICER response to public comments (2026)](https://icer.org/wp-content/uploads/2026/10/ICER_Hypertension_Public_Comment_Grid-For-Publication-102626.pdf)
88. [Idorsia press release, aprocitentan commercialization partnership (2026)](https://www.idorsia.com/investors/news-and-events/media-releases/media-release-details?id=3793976)
89. [Idorsia TRYVIO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217686s005lbl.pdf)
90. [Jacob et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5657494/)
91. [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)
92. [Judge et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12209857/)
93. [Kandzari et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37914510/)
94. [Kandzari et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11549517/)
95. [Kandzari et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12244969/)
96. [Kazi et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38832515/)
97. [Kirkland et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6015342/)
98. [Krieger et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29463627/)
99. [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)
100. [Laffin et al. (2025a)](https://mineralystx.com/wp-content/uploads/2025/03/ACC-2025_ADVANCE-HTN-LBCToral-25MARCH2025.pdf)
101. [Laffin et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/40267417/)
102. [Lee et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11935718/)
103. [Lee et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12079568/)
104. [Lewington et al. (2002)](https://pubmed.ncbi.nlm.nih.gov/12493255/)
105. [Lubitz et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4651757/)
106. [MacLeod et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9536345/)
107. [Mahfoud et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35390320/)
108. [Malhotra et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8271129/)
109. [Malhotra et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11598664/)
110. [Mancia et al. (2023)](https://journals.lww.com/jhypertension/fulltext/2023/12000/2023_esh_guidelines_for_the_management_of_arterial.2.aspx)
111. [Martin et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12256702/)
112. [McEvoy et al. (2024)](https://academic.oup.com/eurheartj/article/45/38/3912/7741010)
113. [Mehra et al. (2026)](https://www.ahajournals.org/doi/10.1161/hyp.83.suppl_1.08)
114. [Million Hearts hypertension cascade (2023)](https://millionhearts.hhs.gov/data-reports/hypertension-prevalence.html)
115. [Mineralys Therapeutics first quarter 2026 results announcement (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/100/mineralys-therapeutics-reports-first-quarter-2026-financial)
116. [Mineralys Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000056/mlys-20251231.htm)
117. [Mineralys Therapeutics Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000144/mlys-20260930.htm)
118. [Mineralys Therapeutics fourth quarter 2025 earnings call transcript (2026)](https://www.fool.com/earnings/call-transcripts/2026/03/12/mineralys-mlys-q4-2025-earnings-call-transcript)
119. [Mineralys Therapeutics fourth quarter 2025 results announcement (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/94/mineralys-therapeutics-reports-fourth-quarter-2025)
120. [Mineralys Therapeutics pipeline](https://mineralystx.com/pipeline/)
121. [Mineralys Therapeutics press release, Advance-HTN ACC.25 presentation (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/66/mineralys-therapeutics-announces-late-breaking-data-from)
122. [Mineralys Therapeutics press release, Advance-HTN NEJM publication (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/67/mineralys-therapeutics-announces-publication-of-pivotal)
123. [Mineralys Therapeutics press release, AHA Hypertension 2026 (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/121/mineralys-therapeutics-presents-new-data-for-lorundrostat)
124. [Mineralys Therapeutics press release, ASN Kidney Week 2025 (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/85/data-for-lorundrostat-in-chronic-kidney-disease-and)
125. [Mineralys Therapeutics press release, board appointments (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/122/mineralys-therapeutics-expands-its-board-of-directors-with)
126. [Mineralys Therapeutics press release, corporate update (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/89/mineralys-therapeutics-provides-corporate-update-and)
127. [Mineralys Therapeutics press release, ENDO 2026 (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/108/mineralys-therapeutics-presents-late-breaking-data-on)
128. [Mineralys Therapeutics press release, ESH 2025 Launch-HTN presentation (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/72/mineralys-therapeutics-announces-late-breaking-presentation)
129. [Mineralys Therapeutics press release, ESH 2026 (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/103/mineralys-therapeutics-presents-new-data-from-the-phase-3)
130. [Mineralys Therapeutics press release, Explore-CKD publication (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/124/mineralys-therapeutics-announces-publication-of-phase-2)
131. [Mineralys Therapeutics press release, Explore-CKD topline results (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/73/mineralys-therapeutics-announces-positive-topline-results)
132. [Mineralys Therapeutics press release, Explore-OSA trial initiation (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/55/mineralys-therapeutics-announces-phase-2-clinical-trial-of)
133. [Mineralys Therapeutics press release, Launch-HTN and Advance-HTN topline results (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/60/mineralys-therapeutics-announces-positive-topline-results)
134. [Mineralys Therapeutics press release, Launch-HTN JAMA publication (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/74/mineralys-therapeutics-announces-journal-of-the-american)
135. [Mineralys Therapeutics press release, Launch-HTN subgroup analyses (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/80/mineralys-therapeutics-presents-subgroup-analyses-of-phase)
136. [Mineralys Therapeutics press release, NDA acceptance and Explore-OSA topline results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/93/mineralys-therapeutics-announces-fda-acceptance-of-nda-for)
137. [Mineralys Therapeutics press release, Tanabe royalty repurchase (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/104/mineralys-therapeutics-announces-repurchase-of-royalty)
138. [Mineralys Therapeutics press release, Target-HTN JAMA publication (2023)](https://ir.mineralystx.com/news-events/press-releases/detail/26/mineralys-therapeutics-announces-jama-publication-of-full)
139. [Mineralys Therapeutics press release, Target-HTN topline results (2022)](https://ir.mineralystx.com/news-events/press-releases/detail/5/mineralys-therapeutics-announces-positive-topline-phase-2)
140. [Mineralys Therapeutics press release, Transform-HTN late-breaker selection (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/116/mineralys-therapeutics-transform-htn-open-label)
141. [Mineralys Therapeutics press release, Transform-HTN results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/129/mineralys-therapeutics-presents-new-late-breaking-data-from)
142. [Mineralys Therapeutics second quarter 2026 results announcement (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/111/mineralys-therapeutics-reports-second-quarter-2026)
143. [Mineralys Therapeutics third quarter 2025 results announcement (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/86/mineralys-therapeutics-reports-third-quarter-2025-financial)
144. [Mineralys Therapeutics third quarter 2026 earnings call transcript (2026)](https://www.tradingkey.com/news/transcripts/262279607-)
145. [Mineralys Therapeutics third quarter 2026 results announcement (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/127/mineralys-therapeutics-reports-third-quarter-2026-financial)
146. [Monticone et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29129575/)
147. [Muntner et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11409525/)
148. [Muntner et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7489367/)
149. [NCD Risk Factor Collaboration (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8446938/)
150. [NCQA Blood Pressure Control for Patients With Hypertension measure](https://www.ncqa.org/report-cards/health-plans/state-of-health-care-quality-report/measures-list/blood-pressure-control-for-patients-with-hypertension-bpc-e/)
151. [NCQA Controlling High Blood Pressure measure](https://www.ncqa.org/report-cards/health-plans/state-of-health-care-quality-report/controlling-high-blood-pressure-cbp/)
152. [Noubiap et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30087099/)
153. [Owei et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12885222/)
154. [Parati et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33390044/)
155. [Pfizer ALDACTONE prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/012151s080lbl.pdf)
156. [Pimenta et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2771382/)
157. [Pollock (2025)](https://pubmed.ncbi.nlm.nih.gov/40802955/)
158. [Queiroga et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13100762/)
159. [Rabbitt et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38009268/)
160. [Rasmussen et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12281267/)
161. [Reddy et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40285540/)
162. [S&P Global Market Intelligence (2026)](https://www.spglobal.com/market-intelligence/en/news-insights/research/2026/07/astrazeneca-s-baxfendy-set-for-blockbuster-sales-after-hypertension-approval)
163. [Sacks et al. (2001)](https://pubmed.ncbi.nlm.nih.gov/11136953/)
164. [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)
165. [Saxena et al. (2026a)](https://www.ahajournals.org/doi/10.1161/hyp.83.suppl_1.FR461)
166. [Saxena et al. (2026b)](https://mineralystx.com/wp-content/uploads/2026/11/MV84448B5_AHA-SS2026-TRANSFORM-OLE-study-ORAL-Upload.pdf)
167. [Saxena et al. supplementary appendix (2025)](https://pmc.ncbi.nlm.nih.gov/articles/instance/12210145/bin/jama-e259413-s001.pdf)
168. [Schlaich et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36356632/)
169. [Shimbo et al. (2020)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000000803)
170. [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)
171. [Sim et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4556588/)
172. [Staplin et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37156250/)
173. [Sullivan and Ghushchyan (2006)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2634296/)
174. [Tajeu et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5215087/)
175. [Taylor et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12230492/)
176. [Teza et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12875774/)
177. [Thomas et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6064834/)
178. [Tortorici et al. (2024)](https://mineralystx.com/wp-content/uploads/2024/09/83964-ACCP-Poster-2024-09-03v2.pdf)
179. [Trevisol et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21045726/)
180. [Tsou et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13587145/)
181. [Tuttle et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38109916/)
182. [US Preventive Services Task Force (2021)](https://jamanetwork.com/journals/jama/fullarticle/2779190)
183. [Velasco et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4562815/)
184. [Vemulapalli et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8218938/)
185. [Viatris INSPRA prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021437s018lbl.pdf)
186. [Victor et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6018053/)
187. [Vogt et al. (2026)](https://www.ovid.com/jnls/jasn/fulltext/10.1681/asn.2026fy6zb248~blood-pressure-and-albuminuria-reduction-with-lorundrostat)
188. [Wallach et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11036312/)
189. [Wang et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11585433/)
190. [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)
191. [WHO Drug Information (2022)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-%28inn%29/pl127.pdf)
192. [Williams et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4655321/)
193. [Williams et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5966620/)
194. [Woode et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37466447/)
195. [World Health Organization hypertension fact sheet (2025)](https://www.who.int/news-room/fact-sheets/detail/hypertension)
196. [Yousif et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13754360/)
197. [Yusuf et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13232938/)
198. [Zeijen et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11356742/)

## Related pages
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Terms and abbreviations](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations.md)
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Product information and disease description](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Clinical evidence](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Economic information and modeling report](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics.md)
